Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S510000
Reexamination Certificate
active
07964627
ABSTRACT:
The present invention relates to novel amino arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them: The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The compounds of the invention are useful in the treatment of various disorders that are related to 5-HT6receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, obesity, anxiety, depression, diseases associated with pain, respiratory diseases, gastrointestinal, cardiovascular diseases and cancer.
REFERENCES:
patent: WO 98/27081 (1998-06-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/37623 (1999-07-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 00/63203 (2000-05-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 02/060871 (2002-08-01), None
patent: WO 02/098857 (2002-12-01), None
patent: WO 02/098878 (2002-12-01), None
patent: WO 03/065046 (2003-08-01), None
patent: WO 03/066056 (2003-08-01), None
patent: WO 03/080580 (2003-10-01), None
patent: WO 2004/035047 (2004-04-01), None
patent: WO 2004/048328 (2004-06-01), None
patent: WO 2004/048330 (2004-06-01), None
patent: WO 2004/048331 (2004-06-01), None
patent: WO 2004/055026 (2004-07-01), None
patent: WO 2007/020652 (2007-02-01), None
CognitiveDisorder, 2010, http://en.wikipedia.org/wiki/Cognitive—disorder.
Alzheimer's Disease Treatment Phases, http://www.alzheimerstreatment.org/treatment/disease-treatment.htm, 2009.
Alzheimer's Drugs, Consumer Reports Best Buy Drugs (p. 1-5), 2009.
Monsma et al., “Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs”, Molec. Pharmacol. 43:320-327 (1993).
Kohen et al., “Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor”, J. Neurochem. 66:47-56 (1996).
Ruat et al., “A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP Accumulation”, Biochem. Biophys. Res. Comm. 193:268-276 (1993).
Ward et al., “Localization of Serotonin Subtype 6 Receptor Messenger RNA in the Rat Brain by in situ Hybridization Histochemistry”, Neurosci. 64:1105-1111 (1995).
Reavill and Rogers, “The Therapeutic Potential of 5-HT6 Receptor Antagonists”, Curr. Opin. Invest. Drugs 2 (1):104-109 (2001).
Stean et al., “Anticonvulsant Properties of the Selective 5-HT6 Receptor Antagonist SB-271046 in the Rat Maximal Electroshock Seizure Threshold Test”, Br. J. Pharmacol. 127 Proc. Supplement 131P (1999).
Routledge et al., “Characterization of SB-271046: A Potent, Selective and Orally Active 5-HT6 Receptor Antagonist”, Br. J. Pharmacol. 130:1606-1612 (2000).
Gerard et al., “Immuno-localization of Serotonin 5-HT6 Receptor-like Material in the Rat Central Nervous System”, Brain Research 746:207-219 (1997).
Bentley et al., “Investigation of Stretching Behaviour Induced by the Selective 5-HT6 Receptor Antagonist, Ro 04-6790, in Rats”, Br. J. Pharmacol. 126(7):1537-1542 (1999).
Dawson et al., “In Vivo Effects of the 5-HT6 Antagonist SB-271046 on Striatal and Frontal Cortex Extracellular Concentrations of Noradrenaline, Dopamine, 5-HT, Glutamate and Aspartate”, Br. J. Pharmacol. 130(1):23-26 (2000).
Rogers et al., “The Selective 5HT6 Receptor Antagonist, SB-271046-A, Enhances Performance of Maze Tasks in the Rat”, Society of Neuroscience, Abstracts 26:680 (2000).
Ernst et al., DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study:, J. Neuroscience 18(15):5901-5907 (1998).
Cole et al., WAY-181187 230th ACS National Meet. (Aug. 28-Sep. 1, 2005 Wash.D.C.) Abstract MEDI 17.
Branchek and Blackburn, “5-HT6 Receptors as Emerging Targets for Drug Discovery”, Ann. Rev. Pharm. Toxicol. 40:319-334 (2000).
Roth et al., “Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine-7 Receptors”, J. Pharmacol. Exper. Therapeut. 268:1403-12 (1994).
Fox et al., “Memory Consolidation Induces a Transient and Time-Dependent Increase in the Frequency of Neural Cell Adhesion Molecule Polysialylated Cells in the Adult Rat Hippocampus.”, J. Neurochem. 65(6):2796-99 (1995).
Wooley et al., “A Role for 5-HT6 Receptors in Retention of Spatial Learning in the Morris Water Maze,” Neuropharmacol. 41:210-29 (2001).
Holenz et al., “Medicinal Chemistry Strategies to 5-HT6 Receptor Ligands as Potential Cognitive Enhancers and Antiobesity Agents”, Drug Discovery Today 11(7/8):283-299 (Apr. 2006).
Glennon et al., “2-Substituted Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors”, J. Med. Chem. 43:1011-1018 (2000).
Tsai et al., “N1-(Benzenesulfonyl)tryptamines as Novel 5-HT6 Antagonists”, Bioorg. Med. Chem. Lett. 10:2295-99 (2000).
Demchyshyn et al., “ALX-1161: Pharmacological Properties of a Potent and Selective 5-HT6 Receptor Antagonist”, 31st Ann. Meet. Soc. Neurosci. Nov. 10-15, Abstr. 266.6 (2001).
Mattson et al., 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as Novel 5-HT6 Receptor Agonists, Bioorg. Med. Chem. Lett. 15:4230-34 (2005).
Pullagurla, MR, Westkaemper RB, Glennon RA, “Possible Differences in Modes of Agonist and Antagonist Binding at Human 5-HT6 Receptors.” Bioorg. Med. Chem. Lett. 14:4569-4573 (2004).
Bromidge et al., “5-Chloro-N-(4-methoxy-3-piperazin-1-yl-pheny1)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist”, J. Med. Chem. 42:202-205 (1999).
Bromidge et al., Phenyl Benzenesulfonamides are Novel and selective 5-HT6 Antagonists: Identification of N-(2,5-Dibromo-3-fluoropheny1)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134), Bioorg. Med. Chem. Lett. 11:55-58 (2001).
Hirst et al., “Characterisation of SB-399885, a Potent and Selective 5-HT6 Receptor Antagonist”, 33rd Ann. Meet. Soc. Neurosci. (Nov. 8-12 New Orleans) Abstr. 576.7 (2003).
Bonhaus et al., “RO4368554, a High Affinity, Selective, CNS Penetrating 5-HT6 Receptor Antagonist”, 32nd Ann. Meet. Soc. Neurosci. Abstr. 884.5 (2002).
Pouzet et al., “Effects of the 5-HT6 Receptor Antagonist, SB-271046, in Animal Models for Schizophrenia”, Pharmacol. Biochem. Behav. 71:635-643 (2002).
Kask et al., “Neuropeptide Y Y5 Receptor Antagonist CGP71683A: The Effects on Food Intake and Anxiety-Related Behavior in the Rat”, Eur. J. Pharmacol. 414:215-224 (2001).
Turnbull et al., “Selective Antagonism of the NPY Y5 Receptor Does Not Have a Major Effect on Feeding in Rats”, Diabetes 51:2441-2449 (2002).
Ennaceur et al., “A New One-Trial Test for Neurobiological Studies of Memory in Rats”, Behav. Brain Res. 31:47-59 (1988).
King et al., “5-HT6 Receptor Antagonists Reverse Delay-Dependent Deficits in Novel Object Discrimination by Enhancing Consolidation—An Effect Sensitive to NMDA Receptor Antagonism”, Neuropharmacol. 47:195-204 (2004).
Berge et al., “Pharmaceutical Salts”, J. Pharm. Sci., 66:1-19 (1977).
Callahan et al., Characterization of the Selective 5-HT6 Receptor Antagonist SB 271046 in Behavioral Models of Cognition, Society for Neuroscience, Abst. 776.19 (2004).
Sleight et al., “Characterization of Ro 04-6790 and Ro 63-0563: Potent and Selective Antagonists at Human and Rat 5-HT6 Receptors”, Br. J. Pharmacol., 124: 556-562 (1998) et al., “Characterization of Ro 04-6790 and Ro 63-0563: Potent and Selective
Jasti Venkateswarlu
Kambhampati Rama Sastri
Kandikere Nagaraj Vishwottam
Ramakrishna Nirogi Venkata Satya
Shinde Anil Karbhari
IpHorgan Ltd.
Loewe Sun Jae Y
Suven Life Sciences Limited
LandOfFree
Amino arylsulfonamide compounds and their use as 5-HT 6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino arylsulfonamide compounds and their use as 5-HT 6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino arylsulfonamide compounds and their use as 5-HT 6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2637015